News

Inaugurated this year, the Gustave Roussy Prize returns in 2026 to honor a researcher whose scientific discoveries have had a major impact on cancer care. Endowed with €200,000, this prestigious international award recognizes groundbreaking contributions to oncology. 

Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.

This quarter, we also learned that the FOLFIRINOX chemotherapy protocol should be favoured over the current standard in locally advanced unresectable pancreatic cancers, that radionuclide therapy in hard-to-treat prostate cancers improves patients’ quality of life in addition to being effective, that two mutations could be targeted to develop new...

Each year, the American Society of Clinical Oncology (ASCO) congress brings together thousands of cancer specialists from around the world to discuss the latest advances in oncology and debate the discoveries that will help transform patient care and develop the treatments of tomorrow. More than 100 studies involving physician-scientists from...

Over the last three months, we also learned that low-dose intestinal irradiation enhances the effectiveness of immunotherapy by acting on the microbiota and immune cells; that a subtype of sarcoma (DSRCT tumours) could be more effectively treated in the future by targeting a specific vulnerability in cancer cells; and that adjusting the dose and...

The American Association for Cancer Research (AACR) annual meeting, held from 25 to 30 April in Chicago, is a major event dedicated to scientific and translational research in oncology. It highlights advances that turn discoveries into tangible clinical applications for patients. Alongside ASCO and ESMO, it is one of the key international...

The Gustave Roussy Foundation is launching an ambitious programme of chairs of excellence to attract and retain the world’s leading cancer researchers. Three inaugural chairs are already operational under the leadership of internationally renowned scientists. The ambition is to accelerate breakthroughs in the fight against cancer.

On 19 March, the 4th edition of the Transatlantic Exchanges took place in Paris—a scientific day co-organised by Gustave Roussy and the Dana-Farber Cancer Institute with support from the Servier Institute. Dr. Toni Choueiri (Dana-Farber) and Prof. Karim Fizazi (Gustave Roussy), co-chairs of the event, reflect on the key themes of this edition,...

Named Gustave Roussy International Egypt, the opening of a cancer centre in Cairo, Egypt, marks the transformation of the Dar Al-Salam-Hermel Oncology Hospital under a brand licensing agreement with Gustave Roussy International, a subsidiary of Gustave Roussy.

In 2024, the Nuclear Safety and Radiation Protection Authority (ASNR) and the Regional Health Agency (ARS) Île-de-France authorised Gustave Roussy to conduct Phase I trials in nuclear medicine, the first stage in the clinical validation process of a new treatment.